The latest Survivorship eNews is out now! With working group updates, new COSA-endorsed resources, journal articles, COSA-IPOS 2025 key survivorship sessions & more. Check your inbox, visit https://t.co/ZJnjJvbXhv, or subscribe via your COSA member account https://t.co/5ib5Nlou8I

Are you interested in how #ImpSci can improve #HealthEquity in #CancerCare? Join this @DaffodilCentre webinar to hear from 3 #ECRs forging the path towards #implementation of more equitable cancer care across the cancer continuum. Register now https://t.co/Jz4hbQ5L0s @syd_health

The Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer (2nd Ed) aims to reduce disparities in cancer outcomes by addressing specific needs and challenges of First Nations people and ensuring competent and culturally safe care https://t.co/HPHgvQlhei

The global burden of liver cancer is increasing, with new cases set to double by 2050. On the cover, the latest Commission report on addressing the global hepatocellular carcinoma burden. This and more in our latest issue 👉 https://t.co/GbLi5Fw6BF

“It’s not enough to have a large amount of data in one place, if we don’t make it matter to clinical teams.” - @DrCandDonn presents on the future of digital analytics for cancer services #NSWCancerSummit2025

Understanding Mixed Effects Models: A Simple Example Imagine researchers are testing a new drug to lower blood pressure. They give the drug to patients in 10 different hospitals and measure how much each patient’s blood pressure drops after taking the drug. Now, two things can

Just used fastml to compare logistic regression (glm/glmnet) and random forest (ranger/randomForest) on the Framingham dataset. Repeated CV + Bayesian tuning (20 iter) with early stopping, MICE imputation, and upsampling made model selection easy. 🚀 library(fastml)

🧠New📰in @APA_Journals #HealthPsychology 🕸️We used network analysis to explore how different components of fear of cancer recurrence (FCR) are interconnected 🎯Findings suggest key intervention targets 📖 Read more: https://t.co/iyImU7wY3C #FCR #PsyOnc #SurvOnc

LATEST NEWS📢| The #DaffodilCentre supported by @cancerNSW is excited to announce the launch of #Refer4Scope - a new online decision tool designed to help #GPs make guideline-appropriate #Colonoscopy referrals. Join us for an @RACGP and @ACRRM accredited #Webinar to gain access

The COSA Annual Report 2024 is available now on our website. Read about progress being made towards our goal of quality multidisciplinary cancer care for all. With reports from the President, CEO, ASM Co-convenors, COSA Groups and Affiliated Organisations. https://t.co/StDQPvXAvr

After two days of amazing participation from health professionals and consumers, co-convenor Michael Jefford is energised to build on the improvements we're seeing in survivorship care. #Surv25

Interesting to still hear the complete fallacy that “walking is enough” and “just moving makes a difference” when thinking of exercise medicine for cancer. Sure, it helps. But it does nothing for muscle or bone health- two tissues with direct links to frailty and premature death.

A thought provoking presentation on the association between work after cancer with financial toxicity by @bogda_koczwara at the #SURV25

Great talk by Assoc Prof Ben Smith @cancer_K2A @DaffodilCentre on Addressing fear of cancer recurrence in routine care at #SURV25

Our 2025 National Cancer Survivorship Conference begins tomorrow. Be prepared for an exciting program showcasing innovations in survivorship care, research, advocacy and policy. Plus opportunities to meet, mingle and collaborate. https://t.co/ONLlO3mfxf #Surv25

👀PhD scholarship opportunity for a talented candidate w/ health services &/or data science background to evaluate a novel community-based model of care using a patient registry and data linkage Closes 30 Apr 📅 Domestic applicants only @DrSuzanneGrant https://t.co/BZZ8qNKCZb

The first edition of series 2 of the podcast is out! Check it out here https://t.co/6wN9p904Ia

🔬NEW RESEARCH👇| Lowering the screening start age to 45 or 40 could reduce colorectal cancer (CRC) mortality by 5% and 10%, respectively. Meanwhile, extending the stop age to 79 or 85 could lead to a 3% and 5% reduction. 🔍The findings suggest that starting earlier is more

Want to learn about #implementation of #Cancer #FearofRecurrence research in practice? Please join this #webinar on Wed Feb 26 featuring: @DrSophielebel 🇨🇦FCR guideline author @DanielHallPhD 🇺🇸 FCR guideline advocate Me, 🇦🇺FCR clinical pathway author 9am AEDT for 🇦🇺 folks

New paper from our @DaffodilCentre team, led by Dr Stephen Wade: Using Bayesian evidence synthesis to quantify uncertainty in population trends in smoking behaviour: https://t.co/IX4shfucWN